November 16, 2021
A key European advisory panel after a re-examination procedure has again spurned Kyowa Kirin’s Parkinson’s disease drug istradefylline as an add-on treatment to levodopa-based regimens in adult patients experiencing “off” episodes. The company said on November 15 that the European...read more